Analyzing ICU Medical (NASDAQ:ICUI) and ClearPoint Neuro (NASDAQ:CLPT)

ClearPoint Neuro (NASDAQ:CLPT) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares ClearPoint Neuro and ICU Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-59.64%	-62.10%	-38.39%
ICU Medical	-4.74%	5.05%	2.42%

Insider & Institutional Ownership

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 7.0% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 1.5% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

ClearPoint Neuro has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Earnings & Valuation

This table compares ClearPoint Neuro and ICU Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$31.39 million	10.60	-$22.09 million	($0.76)	-15.64
ICU Medical	$2.42 billion	1.31	-$29.66 million	($3.83)	-33.68

ClearPoint Neuro has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for ClearPoint Neuro and ICU Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	0	0	3	0	3.00
ICU Medical	0	1	2	1	3.00

ClearPoint Neuro presently has a consensus target price of $25.00, suggesting a potential upside of 110.26%. ICU Medical has a consensus target price of $192.67, suggesting a potential upside of 49.37%. Given ClearPoint Neuro’s higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than ICU Medical.

Summary

ClearPoint Neuro beats ICU Medical on 8 of the 14 factors compared between the two stocks.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.